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Abstract
Constitutive JAK-STAT pathway activation occurs in most myeloproliferative
neoplasms as well as in a significant proportion of other hematologic
malignancies, and is frequently a marker of poor prognosis. The underlying
molecular alterations are heterogeneous as they include activating mutations in
distinct components (cytokine receptor, JAK, STAT), overexpression (cytokine
receptor, JAK) or rare JAK2 fusion proteins. In some cases, concomitant loss of
negative regulators contributes to pathogenesis by further boosting the activation
of the cascade. Exploiting the signaling bottleneck provided by the limited
number of JAK kinases is an attractive therapeutic strategy for hematologic
neoplasms driven by constitutive JAK-STAT pathway activation. However, given
the conserved nature of the kinase domain among family members and the
interrelated roles of JAK kinases in many physiological processes, including
hematopoiesis and immunity, broad usage of JAK inhibitors in hematology is
challe...
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Introduction
Mature blood cells have a limited lifespan and are continu-
ously renewed through a multi-step process called
hematopoiesis, initiated in the bone marrow by the prolifer-
ation and differentiation of a small population of pluripotent
hematopoietic stem cells (Figure 1). Undergoing asymmetric
divisions, hematopoietic stem cells have the ability to replen-
ish their pool by self-renewal and to differentiate into lineage-
committed progenitors with increasingly restricted potential
which will ultimately give rise to all specialized blood cells.1
A network of hematopoietic cytokines dictates the fate (pro-
liferation, differentiation or apoptosis) of the various progen-
itors, thereby maintaining steady state levels of blood cells in
the periphery or inducing amplification of specific cell types
in response to particular stimuli to meet physiological needs.
Abnormalities in the hematopoietic program disrupt home-
ostasis and drive the accumulation of intermediate progeni-
tors and/or mature cells in the bone marrow, blood and/or
peripheral lymphoid organs resulting in a variety of malig-
nancies.2
Overview of the JAK-STAT pathway
Hematopoietic cytokines bind to their cognate receptors at
the surface of target cells; the receptors are composed of at
least two single membrane-spanning chains. Except for sever-
al tyrosine kinase receptors, such as c-kit, Fms-like tyrosine
kinase 3 (FLT3) or the receptor for macrophage colony-stim-
ulating factor (M-CSF), the intracellular part of hematopoietic
receptor chains lacks intrinsic enzymatic activity. However,
these receptor chains constitutively and specifically associate
with a member of the Janus kinase family (JAK1, JAK2, JAK3
or TYK2) in order to form functional complexes capable of
transducing ligand-induced signals. Following cytokine
engagement, receptor chains re-orientate or oligomerize lead-
ing to juxtaposition, and hence transactivation of the two
associated JAK. Once activated, JAK phosphorylate tyrosine
residues in the cytoplasmic part of the receptor creating dock-
ing sites for downstream Src homology-2 (SH2) domain-con-
taining adaptor and effector proteins. Depending on the
amino acids surrounding the phosphotyrosine, any one or
more of the seven signal transducer and activator of transcrip-
tion factors (STAT-1, -2, -3, -4, -5a, -5b and -6) can be recruit-
ed and phosphorylated at the receptor, homo- or het-
erodimerize and translocate into the nucleus to regulate tran-
scription of target genes.3
The JAK-STAT pathway constitutes a signal transduction
system through which a large spectrum of extracellular
cytokines and nearly as many cognate transmembrane recep-
tors converge towards an intracellular code employing four
JAK kinases and seven STAT factors.4 Signal specificity down-
stream of cytokine receptors is achieved by the nature of the
STAT dimers formed at the receptor, the kinetics and intensi-
ty of STAT activation as well as the triggering of additional
signaling pathways such as mitogen-activated protein kinases
(MAPK) and phosphatidylinositol-3’-kinase (PI3K). Transient
JAK-STAT pathway activation is guaranteed by several mech-
anisms of negative regulation which operate at each step of
signal transduction, such as ubiquitin-mediated receptor
internalization, dephosphorylation of tyrosines in the JAK
activation loop by constitutive phosphatases and induction of
suppressor of cytokine signaling (SOCS) proteins.5
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Constitutive JAK-STAT pathway activation occurs in most myeloproliferative neoplasms as well as in a significant
proportion of other hematologic malignancies, and is frequently a marker of poor prognosis. The underlying
molecular alterations are heterogeneous as they include activating mutations in distinct components (cytokine
receptor, JAK, STAT), overexpression (cytokine receptor, JAK) or rare JAK2 fusion proteins. In some cases, con-
comitant loss of negative regulators contributes to pathogenesis by further boosting the activation of the cascade.
Exploiting the signaling bottleneck provided by the limited number of JAK kinases is an attractive therapeutic strat-
egy for hematologic neoplasms driven by constitutive JAK-STAT pathway activation. However, given the con-
served nature of the kinase domain among family members and the interrelated roles of JAK kinases in many phys-
iological processes, including hematopoiesis and immunity, broad usage of JAK inhibitors in hematology is chal-
lenged by their narrow therapeutic window. Novel therapies are, therefore, needed. The development of more
selective inhibitors is a questionable strategy as such inhibitors might abrogate the beneficial contribution of alle-
viating the cancer-related pro-inflammatory microenvironment and raise selective pressure to a threshold that
allows the emergence of malignant subclones harboring drug-resistant mutations. In contrast, synergistic combi-
nations of JAK inhibitors with drugs targeting cascades that work in concert with JAK-STAT pathway appear to
be promising therapeutic alternatives to JAK inhibitors as monotherapies. 
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ABSTRACT
In 2005, several groups reported a unique, acquired,
somatic activating mutation of JAK2 (V617F) in 95% of
patients with polycythemia vera (PV) and in about half of
those with essential thombocythemia (ET) or primary
myelofibrosis (MF).6-9 The discovery of JAK2V617F led to
screening for JAK mutations in other hematologic neo-
plasms. Thanks to improvements of sequencing tech-
niques and the conduction of massive sequencing projects,
the catalogue of genetic alterations in hematologic malig-
nancies is constantly being updated as ever more new
mutational targets are discovered. This review provides an
overview of the different molecular mechanisms underly-
ing constitutive activation of the JAK-STAT pathway and
their respective frequencies among hematologic neo-
plasms. The use of JAK inhibitors in the clinic and in ongo-
ing trials, resistance phenomena as well as future chal-
lenges are discussed. The review begins by documenting
insights into the structural organization of JAK kinases,
their mode of activation as well as the role of the different
family members in hematopoiesis.
Janus kinases
JAK1, JAK2 and TYK2 tyrosine kinases are ubiquitously
expressed and non-covalently bound to a distinct, mostly
non-overlapping repertory of receptor chains. By contrast,
JAK3 expression is restricted to the hematopoietic lineage
and it associates exclusively with the common gamma-
chain (γc). Based on their primary sequences, JAK kinases
were initially divided into seven highly conserved JAK
homology regions (JH1-7, starting from the C-terminal
end) but were subsequently organized into four functional
domains.10
The N-terminal moiety of JAK kinases constitutes the
receptor-binding module with a FERM (band 4.1, ezrin,
radixin, moesin) domain (JH4-7) and an atypical SH2
domain (JH3).11 It has been experimentally established that
both domains do not exist as individual functional entities
but structurally cooperate for non-covalent anchoring to
two membrane-proximal regions of defined receptors.12,13
This was corroborated by a recent crystal structure study
showing that the N-terminal part of TYK2 forms a con-
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Figure 1. Hematopoiesis. Hematopoiesis originates from a hematopoietic stem cell, which can undergo either self-renewal or hierarchical differen-
tiation into lineage-committed progenitors with decreasing potential that ultimately will give rise to all mature blood cells. Cytokines and their recep-
tor-associated JAK necessary for the progenitors to pass through the different maturation steps are indicated. HSC: hematopoietic stem cell; CMP:
common myeloid progenitor; CLP: common lymphoid progenitor; GM: granulocyte macrophage progenitor; BCP: B cell progenitor; TNK: T and na -
tural killer cell progenitor; EP: erythroid progenitor; Mk: megakaryocyte; GP: granulocyte progenitor; MP: macrophage progenitor; TPO: thrombopoi-
etin; SCF: stem cell factor; IL: interleukin; GM-CSF: granulocyte/monocyte colony-stimulating factor; G-CSF: granulocyte colony-stimulating factor;
M-CSF: monocyte colony-stimulating factor; TSLP: thymic stromal-derived lymphopoietin.
tiguous, Y-shaped receptor-binding module that interacts
with the interferon alpha receptor 1 (IFNAR1) via a com-
posite interface formed by the FERM and SH2 domains.14
The selectivity of the JAK member engaged by a particular
receptor chain does not exclusively depend on intrinsic
sequences within its cytoplasmic domain but also on the
stoichiometry of the receptor. For example, forced
homodimers of chimeric receptors encompassing the
intracellular part of interleukin (IL)-2 receptor (R) β subunit
fused to the extracellular part of erythropoietin (EPO)-R
activated JAK2 despite the fact that the naturally activated
kinase was JAK1.15 Of note, JAK-receptor association is
needed to ensure proper trafficking and localization of the
complex to the plasma membrane.16-18
The C-terminal moiety of JAK contains the catalytic
kinase domain (JH1), whose active conformation is stabi-
lized upon phosphorylation of tandem tyrosine residues in
its activation loop. Inappropriate kinase activity of JH1 in
the absence of stimulus is prevented by a directly adjacent
pseudo-kinase domain (JH2).19 The precise molecular
mechanism by which JH2 regulates JAK activity remains
incompletely understood but insights have been provided
by recent research.20 The pseudokinase domain has long
been considered as catalytically inactive because it lacks
critical conserved residues needed for phosphate coordina-
tion and transfer such as the nearly invariant aspartic acid
in the catalytic site and the third glycine of the GxGxφG
motif in the ATP-binding loop. However, JAK2 JH2 crystal
structure analysis revealed that the pseudo-kinase domain
adopts a classical bilobal kinase fold and binds ATP in a
non-canonical mode.21 The precise function of the
nucleotide binding of JH2 is still debated. JH2 has been
demonstrated to phosphorylate two negative regulatory
sites of JAK2, namely Ser523 in the SH2-JH2 linker and
Tyr570 in JH2 itself.22 Whether this weak kinase activity is
relevant for autoinhibition is still a matter of controversy
since those residues are not conserved among other family
members and disruption of JH2 nucleotide binding does
not lead to constitutive JAK2 activation. Rather, it has
been proposed that JH2 constitutively binds ATP without
hydrolysis, making ATP an essential structural stabilizer of
JH2.23
Studies of recombinant JH1 and JH1-JH2 constructs
from JAK2 showed that the presence of JH2 drastically
decreases JH1 kinase activity by increasing the Km for
ATP possibly via an interdomain interaction that changes
the conformation of JH1.24 Using the recently solved crys-
tal structure of JH1-JH2 from TYK2, this intramolecular
inhibitory interface has been localized near the JH1 cat-
alytic site and is predominantly mediated by the N-lobes
of each domain.25 The JH1-JH2 crystal structure of TYK2
supports an in cis mode of inhibition with the pseudoki-
nase domain inhibiting the directly adjacent kinase
domain within the same protein. Nevertheless, it is
unclear whether this intramolecular JH1-JH2 interplay is
operative in the contest of a physiological receptor.
Because cytokine receptor complexes crucially comprise
two or more subunits, each associated with a JAK
monomer, it cannot be excluded that there is an in trans
mechanism of inhibition in which the pseudokinase
domain of one JAK molecule locks the kinase domain of
the opposing JAK. Recently, Brooks et al. used fluorescence
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Figure 2. Hematopoietic cytokine-receptor complexes. Hetero- or homo-oligomerized receptor chains specifically engage a member of the JAK kinas-
es in order to form signaling-competent hematopoietic receptor complexes. Myelopoiesis is driven by cytokines whose receptors signal through the
transactivation of a pair of juxtaposed JAK2 molecules. Lymphopoiesis is mostly driven by interleukins that bind to the shared γc-receptor family,
which signals through the cooperative action of JAK1 and JAK3. JAK2 and JAK1 participate in the signaling of TSLP, a cytokine involved in late devel-
opment of B-lymphocytes. JAK1, JAK2 and TYK2 can work as partners whereas JAK3 works exclusively in concert with JAK1. JAK2 is the only family
member that can function with itself as opposing JAK. EPO: erythropoietin; TPO: thrombopoietin; G-CSF: granulocyte colony-stimulating factor; IL:
interleukin; GM-CSF: granulocyte/monocyte colony-stimulating factor; TSLP: thymic stromal-derived lymphopoietin.
resonance energy transfer (FRET) to monitor the move-
ments of JAK2 JH1 and JH2 domains during stimulation of
the homodimeric growth hormone receptor. Activation
resulted in an increase in distance between the two JH2
while bringing the two JH1 in closer vicinity, consistent
with the in trans inhibition model.26 Evidence supporting
both the in cis and in trans inhibition models could be rec-
onciled by the hypothesis that distinct mechanisms oper-
ate between different JAK family members or that the
type of associated receptor governs the mode of regula-
tion.27
Role of JAK kinases in hematopoiesis
As outlined in Figure 1, JAK2 plays a role in the function
and maintenance of hematopoietic stem cells28 by partici-
pating directly in signal transduction of thrombopoietin
(TPO)29 and by contributing to signaling downstream of
the stem cell factor.30 JAK2 is also crucial at various stages
of myelopoiesis through binding to receptors for EPO,
TPO, granulocyte colony-stimulating factor (G-CSF), gran-
ulocyte/macrophage colony-stimulating factor (GM-CSF),
IL-3 and IL-5. EPO-R exists as a preformed homodimer,31
while the receptors for TPO and G-CSF are believed to
homodimerize upon ligand binding. Receptors for GM-
CSF, IL-3 and IL-5 consist of heterodimers of a cytokine-
specific a chain and the common β chain that assemble as
ligand-induced tetramers. In all cases, signal transduction
results from transactivation of a pair of juxtaposed JAK2
molecules.
By contrast, JAK1 cooperates with JAK3 for lym-
phopoiesis by binding to heterodimeric receptors of the
common γc family, IL-2R, IL-4R, IL-7R and IL-15R with
JAK1 anchored to the specific chain and JAK3 to the com-
mon γc. Both kinases play obligatory and non-redundant
functions as cells lacking either JAK1 or JAK3 are unable to
respond to γc cytokines.32,33 However, the catalytic activity
of each partner is not of equal importance since a kinase-
dead form of JAK3 but not JAK1 still allows signal trans-
duction via these receptors.34 Thus, in the context of γc-
containing receptors, JAK1 functions as the primary sig-
naling effector whereas JAK3 serves as a scaffold and part-
ner of JAK1. JAK2 in concert with JAK1 could possibly be
implicated in late development of immature B-lympho-
cytes through signaling downstream of thymic stromal-
derived lymphopoietin (TSLP).35 With respect to their
implication in the maturation and amplification of the dif-
ferent myeloid and lymphoid lineages (Figure 2), genetic
alterations leading to oncogenic activation of particular
hematopoietic cytokine receptor complexes give rise to
neoplasms of corresponding cell types. 
Activating alterations of JAK kinases
Hematologic malignancies have been associated with
activating alterations in the four members of the JAK fam-
ily; the frequencies of these alterations differ, with the
majority of them being point mutations. Contrasting with
the dominance of the JAK2V617F mutation in myeloprolifer-
ative neoplasms (MPN), the mutations described later in
other hematologic malignancies in JAK1, JAK2, JAK3 and
more recently in TYK2 are much more heterogeneous
both regarding the mutated residues and the frequency of
mutation in a given disease. The JAK2 locus can also be
involved in translocations resulting in the overexpression
of wild-type JAK2 or the generation of constitutively
active fusion proteins. Figure 3 gives a general overview of
the different myeloid and lymphoid neoplasms for which
the overall frequency of analyzed cases with genetic alter-
ations affecting any component of the cytokine receptor-
JAK-STAT axis reached at least 10%.
Frequencies of alterations in JAK kinase genes among
hematologic malignancies
In accordance with its role in lymphopoiesis, activating
mutations of JAK1 have been described in lymphoid neo-
plasms with their frequency being highest in T-cell acute
lymphoblastic leukemia (ALL) (6.5-27%)36-38 and lower in
B-cell ALL (1.5%)39 and T-cell prolymphocytic leukemia
(8-12.5%).40-42 JAK1 mutants have also been reported in
very rare cases of acute myeloid leukemia.43
As already mentioned, the JAK2V617F mutation is highly
prevalent in classical MPN so that screening for this muta-
tion has become a standard diagnostic procedure. The
same JAK2V617F mutation was described later in a small pro-
portion of patients with atypical MPN,44 and in some with
myelodysplastic syndromes, particularly in patients suffer-
ing from refractory anemia with ringed sideroblasts and
thrombocythemia.45 In addition, mutations in the exon 12
of JAK2 were described in JAK2V617F-negative PV patients
who typically had isolated erythrocytosis.46
JAK2 mutations were also found in lymphoid malignan-
cies such as high-risk B-ALL (8.5%)39 and B-ALL associated
with Down syndrome (18-28%).47-53 Notably, the vast
majority of lymphoid lineage JAK2 mutations affect the
R683 residue in JH2. Interestingly, JAK2 R683 variants are
frequently associated with the overexpression of CRLF2,
suggesting that this cytokine receptor chain is involved in
the functional signaling platform of these mutants.54
CRLF2 is a JAK2-binding chain that together with IL-7Ra
and JAK1 forms the functional receptor complex for TSLP.
The rationale for the specific association of JAK2V617F with
MPN and JAK2R683 with ALL is speculative. The JAK2V617F
mutant might be more efficient in transactivating another
JAK2 in homodimeric cytokine receptor complexes such
as EPO-R or TPO-R, whereas conversely the JAK2R683 vari-
ants might preferentially activate a JAK1 molecule in the
heterodimeric TSLP receptor complex. Alternatively, the
two mutants might differ in their affinity for a particular
receptor chain, substrate specificity or intensity of signal
transduction.
Rare chromosomal rearrangements juxtaposing the
kinase domain-coding portion of the JAK2 gene to
genomic regions coding for the oligomerization domain
of either TEL, BCR, PCM1, Pax5 or ETV6 were described
essentially in ALL and several cases of atypical chronic
myeloid leukemia.51,55-59 The resultant fusion proteins
oligomerize, facilitating transphosphorylation of the
JAK2 activation loops, and constitutively trigger several
downstream signal transduction pathways, such as
STAT5,55 PI3K60 or the MAP kinase,61 independently of the
presence of anchoring receptors. Interestingly, although
artificial chimeric TEL-JAK1, TEL-JAK3 and TEL-TYK2
proteins are able to sustain cytokine-independent growth
of Ba/F3 cells,62 there is no patient-derived chromosomal
translocation that fuses the kinase domain of JAK1, JAK3
or TYK2 to a dimerizer described so far. This is probably
related to an intrinsic genetic instability of the JAK2 locus,
which can otherwise also be subject to amplifications in
30-50% of Hodgkin lymphomas and primary peripheral
B-cell lymphomas.63-65
Gain-of-function mutations in JAK3 are scattered
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throughout the different functional domains and are found
in diverse malignancies of both myeloid and lymphoid ori-
gins. JAK3 mutations were initially described in acute
megakaryoblastic leukemia samples (15%)66 and subse-
quently identified in juvenile myelomonocytic leukemias
(12%).67 With regards to malignancies of lymphoid line-
age, JAK3 mutations were reported in a significant propor-
tion of T-ALL,68 especially in an aggressive subtype called
early T-cell precursor-ALL,38 as well as in diverse mature T-
cell neoplasms.40,42,69-71
More recently, TYK2 mutants were discovered in T-ALL
(21%) and seem to promote cell survival via activation of
STAT1 downstream of IL-10R and upregulation of the
anti-apoptotic BCL2 protein.72
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Figure 3. Frequencies of genetic
alterations affecting the recep-
tor-JAK-STAT axis among hema-
tologic malignancies. Diagrams
give an overview of the maximal
overall frequency of cases with
genetic alterations of the recep-
tor-JAK-STAT axis in (A) myeloid
lineage, (B) lymphoid progenitors
and (C) lymphoid mature cells
disorders (see next page). The
overall frequency (i.e. the sum of
the individual mutation frequen-
cies for each component among
the different references) is indi-
cated in yellow while the
absolute contributions of each
are detailed using a specific color
code (yellow for JAK1, orange for
JAK2, green for JAK3, turquoise
for TYK2, pink for cytokine recep-
tors, black for STAT3, red for
STAT5b and gray for STAT6).
Schematic protein representa-
tions are used to localize the
identified point mutations with
the affected functional domains
indicated in red. In some cases,
other genetic lesions and clinical
associations are described. MPN:
myeloproliferative neoplasms;
PV: polycythemia vera; ET: essen-
tial thrombocythemia; MF:
myelofibrosis; CNL: chronic neu-
trophilic leukemia; CML: chronic
myeloid leukemia; JMML: juve-
nile myelomonocytic leukemia;
AMKL: acute megakaryoblastic
leukemia; ALL: acute lym-
phoblastic leukemia; DS: Down-
syndrome; T-PLL: T-prolympho-
cytic leukemia; ATLL: adult T-cell
lymphoma; NKTCL: NK/T-cell
lymphoma; NK- and T-LGL: NK-
and T-large granular lymphocytic
leukemia; PMBL: primary medi-
astinal B-cell lymphoma; HL:
Hodgkin lymphoma. Figure 3 –
continues on the next page
A
B
Characterization of JAK mutants
Functional characterization of the different JAK variants
revealed that they display common features as well as
mutant-specific particularities. As demonstrated for JAK1,
JAK2 and JAK3, mutants require a functional FERM
domain and the presence of anchoring homo- or het-
erodimeric cytokine receptors to promote signaling and
cell transformation.73-75 One notable exception is the
JAK1L910P mutant that exhibits residual activity upon inac-
tivating mutation in its FERM-domain.75 JAK1 mutants
can trigger STAT activation via IL2-Rβ or IL-9Ra homo -
dimers without need for JAK3 and γc.74 By contrast, JAK3
mutants (with the exception of JAK3L857Q) are strictly
dependent on JAK1 kinase activity.76 Intrinsic specificity
among distinct mutants of the same JAK is illustrated by
qualitative and quantitative differences in STAT activa-
tion, FERM-domain requirement, susceptibility to JAK
inhibitors and, concerning the JAK1 mutants, sensitivity
to type-I interferons.75-78
The overwhelming majority of activating JAK muta-
tions occur in the pseudokinase domain (JH2). The mech-
anism through which such mutations increase the activity
of the kinase domain was almost exclusively studied for
JAK2V617F. Superimposing the crystal structures of the
pseudokinase domains of JAK2V617F and the analogous
JAK1V658F mutants with their wild-type counterparts high-
lighted a stiffening and extension of the aC helix mediated
by the action of a phenylalanine triad.21,79 The aromatic
ring of the phenylalanine at position 617 in JAK2 and 658
in JAK1 fills in the site normally occupied by that of a
highly conserved phenylalanine residue in the SH2-JH2
linker (F537 in JAK2 and F575 in JAK1) thereby inducing
the rotation of a third phenylalanine located in the aC
helix (F595 in JAK2 and F636 in JAK1). Replacement of
either partner of this F-F-F triad by non-aromatic residues
diminishes constitutive kinase activity.79,80 Interestingly,
JAK2V617F is transferable to JAK1 and TYK2 but not JAK3
evoking a different autoinhibition mechanism of JAK3
compared to the three others.81
Besides JAK2V617F, most of the cancer-associated muta-
tions in the pseudokinase domain of JAK1, JAK2 and JAK3
are clustered in the N-lobe and the SH2-JH2 linker frag-
ment. Mapping of the analogous affected residues on the
crystal structure of TYK2 revealed that they localize in or
JAK kinase targeting in hematologic malignancies
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Figure 3 – continued from the
previous page. For abbreviations
and explanations see footnote.
C
near the JH1-JH2 interface and probably relieve the
inhibitory influence.25 On the other side of the interface,
all known kinase N-lobe mutations participate directly in
the JH1-JH2 interaction. 
Activating alterations in cytokine receptors 
The first mechanism of constitutive receptor activation
involves point mutations or small insertions/deletions of
residues located in and around the transmembrane
domain which result in reorientation or dimerization of
unliganded chains. Several examples are listed hereunder.
TPO-R has an intracytoplasmic juxtamembrane amphi-
pathic motif necessary for preventing its activation in the
absence of ligand.82 Mutations in this motif (W515K/L/A)
were described in 5% of patients with JAK2V617F-negative
MF or ET83,84 and were shown to change the spatial confor-
mation of the receptor enabling TPO-independent JAK2
transphosphorylation.85 Additionally, mutations in the
transmembrane domain of TPO-R (S505N and S505A)
cause familial ET.86 Small in-frame insertions/deletions in
the transmembrane domain of IL-7Ra were found in
about 10% of T- and B-ALL.87,88 These sequence modifica-
tions often introduce an unpaired cysteine in the trans-
membrane domain and promote formation of intermolec-
ular disulfide bonds between IL-7Ra mutant subunits,
thereby driving constitutive signaling via JAK1 and inde-
pendently of IL-7, γc or JAK3.87 Point mutations inserting a
cysteine into the extracellular domain of IL-7Ra (S185C)
and CRLF2 (F232C) were identified in a few B-ALL cases
and could act via the same activation mechanism.89
Membrane-proximal mutations of CSF3R (T615A and
T618I), the receptor for G-CSF, are highly prevalent in
atypical chronic myeloid leukemia and in chronic neu-
trophilic leukemia, and induce ligand-independent activa-
tion of the receptor by a mechanism that remains to be
elucidated.90,91 More recently, a whole-exome sequencing
study provided the first report of two concomitant
sequence modifications in γc (a small deletion in the trans-
membrane domain and the K315E mutation in the intra-
cellular part) detected in a sample of T-cell prolymphocytic
leukemia.41 The significance of this finding is not yet clear
as only one patient in a series of 50 analyzed harbored
these γc mutations.
A second mechanism of receptor activation has been
described in patients with chronic neutrophilic leukemia
or atypical chronic myeloid leukemia and involves trunca-
tions of the cytoplasmic tail of CSF3R, leading to escape of
negative regulation.90 The truncated proteins are the result
of frameshift or nonsense mutations and increase the pro-
liferative signal by impairing receptor internalization and
altering the interaction with negative regulators such as
SOCS3. Interestingly, proliferation of cells transformed
with these mutants was relatively insensitive to JAK2
inhibitors, but could be efficiently blocked by SRC
inhibitors, such as dasatinib, indicating that SRC signaling
could be preferentially activated by these truncations.
CSF3R truncating mutations were very recently identified
in 2% of pediatric acute myeloid leukemias.92
The last reported cytokine receptor alteration is overex-
pression of CRLF2, which has already been mentioned in
this review. CRLF2 is aberrantly expressed in 50% of
patients with Down syndrome ALL and in 10% of non-
Down syndrome ALL,54,89,93,94 essentially due to chromoso-
mal rearrangements juxtaposing the CRLF2 locus to the
immunoglobulin heavy chain enhancer or P2RY8 promot-
er. In B-ALL, CRLF2 overexpression in frequently associat-
ed with JAK2R683 variants or IL-7Ra mutations, suggesting
that concomitant genetic events affecting components of
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Figure 4. Mechanisms of consti-
tutive JAK-STAT pathway activa-
tion in hematologic malignan-
cies. The molecular mechanisms
underlying constitutive activation
of the JAK-STAT pathway are
depicted and can affect all the
components of the cascade
(receptors, JAK, STAT, negative
regulators). They can result from
small nucleotide sequence modi-
fications (mutations, insertions,
deletions) or larger changes at
the chromosomal level (translo-
cations and epigenetic changes).
the TSLP-receptor complex are required for its oncogenic
potency.
Taken together, gain-of-function cytokine receptor alter-
ations are diverse and encompass mutations in the trans-
membrane region which induce ligand-independent
receptor dimerization/activation, cytoplasmic tail trunca-
tions that abolish negative regulation and chromosomal
translocations that enhance protein expression. At pres-
ent, such genetic modifications are well established for
TPO-R, CRLF2, IL-7Ra and CSF3R but it is not excluded
that whole-exome sequencing studies will identify alter-
ations in other cytokine receptor chains as suggested by
the recent finding of very rare mutations in γc.
Calreticulin mutations in JAK2 and thrombopoietin
receptor mutation-negative essential thrombocythemia
and myelofibrosis
In December 2013, the molecular diagnostic gap that
remained after the discovery of TPO-R mutations in JAK2-
negative ET and MF patients was partially filled. Two
independent groups reported that 25% of ET and MF
patients had small insertions/deletions in an unexpected
gene coding for calreticulin (CALR), a lectin chaperone
involved in the folding quality control machinery of the
endoplasmic reticulum and in calcium homeostasis.95,96 All
identified sequence modifications invariably provoked a
+1 base shift to the same alternative open reading frame
resulting in the generation of a novel C-terminus with
impaired calcium-binding and loss of the endoplasmic
reticulum-retention motif, although there was no differ-
ence in the pattern of subcellular localization of wild-type
CALR and mutant forms.95 Expression of the most fre-
quent CALR mutant caused transformation to cytokine-
independent cells with phosphorylation of STAT5 by
means of a still unknown mechanism but the homogene-
ity within the frameshifted variants evokes a strong selec-
tive pressure towards newly acquired functionalities
rather than loss-of-function alterations.96 JAK2, TPO-R and
CALR mutations were mutually exclusive genetic events
in MPN with the 10% of triple-negative cases having the
worse prognosis.
Activating mutations in STAT factors
At present, STAT3 and STAT5b mutations have only
been demonstrated in T-cell and natural killer (NK)-cell
leukemias, while mutations of STAT6 have been associat-
ed with B-cell lymphomas. However, given the crucial
function of STAT factors in stages of hematopoiesis, it can
be expected that further sequencing studies will reveal a
role for mutations of STAT family genes in the pathogen-
esis of other hematologic malignancies of different origins.
STAT3 mutations
The occurrence of STAT3 mutations stressed the com-
mon molecular pathogenesis of chronic lymphoprolifera-
tive disorders of NK cells and T-cell large granular lympho-
cyte leukemia, as similar percentages (27-30%) of patients
with these  two disease entities carry these somatic muta-
tions.97,98 Altogether, eight different substitutions clustered
in the exon 21 coding for the SH2 domain have been iden-
tified and all affected residues map at the interface of
STAT dimers. In vitro studies showed that Y640F and
D661V mutants are constitutively phosphorylated and
localize in the nucleus. Patients with STAT3 mutations
presented more often with disease-related autoimmune
phenomena, such as rheumatoid arthritis and autoim-
mune hemolytic anemia, than did patients without these
mutations.97,98 An overproduction of immune cytokines or
a better resistance to apoptosis in the STAT3-mutated
large granular lymphocyte leukemia cell population,
including auto-reactive T cells, might explain this clinical
association.
STAT5b mutations
Two different proven gain-of-function STAT5b muta-
tions (Y665F and N642H) were found in 2% of STAT3
mutation-negative patients with T-large granular lympho-
cyte leukemia with the N642H substitution being associ-
ated with an aggressive, fatal disease course.99 These same
mutations and other new ones were later found in 36% of
cases of T-cell prolymphocytic leukemia, with this being a
higher frequency than that of all other mutated JAK-STAT
components (JAK1, JAK3, IL-7Ra and γc) in the analyzed
cohort.41 STAT5b mutations are uncommon in T-ALL but
their occurrence underlines the significance of the IL7R-
JAK-STAT5 pathway in the pathogenesis of T-ALL.100
Interestingly, while STAT5b mutant blasts were resistant
to JAK inhibitors, the cells were highly sensitive to
inhibitors of STAT5b targets such as anti-apoptotic BCL-2
proteins.100
STAT6 mutations
Identification of heterozygous point mutations in the
DNA binding domain of STAT6 in 36% of PMBCL repre-
sented the first observation of recurrent STAT mutations
in human cancers.101 Very recently, additional activating
STAT6 substitutions were described in 11% of follicular
lymphomas and were demonstrated to prolong residency
of STAT6 in the nucleus, resulting in an exaggerated tran-
scriptional response to the IL-4 highly present in the tumor
microenvironment.102
Loss of negative regulators 
The activation of the JAK-STAT pathway is limited in
time and amplitude by several regulatory mechanisms. For
instance, constitutive phosphatases serve as quenchers of
phosphotyrosines involved in activation and recruitment.
Additionally, inducible regulators of the SOCS family
mediate ubiquitin-tagging for proteasomal degradation of
the receptor complex, suppression of JAK catalytic activity
or competition with STAT factors for docking sites on
receptors. Loss-of-function alterations or epigenetic silenc-
ing affecting genes involved in the repression process are
expected to result in more intense and sustained cytokine
receptor signaling. Some illustrative examples are docu-
mented in this section. 
PTPN2 is a protein tyrosine phosphatase (PTP) able to
dephosphorylate tyrosine residues located in the activa-
tion loop of JAK1 and JAK3.103 Mono- or bi-allelic inactiva-
tion of PTPN2 through deletion of the entire gene locus
was found in 6% of T-ALL cases,104 sometimes together
with JAK1-activating mutations.104 Down-regulation of
PTPN2 sensitizes to JAK1- but not JAK2-mediated trans-
formation and reduces the sensitivity of transformed cells
to JAK inhibitors.105 Similarly, loss-of-function mutations
of CD45, another JAK-regulating phosphatase encoded by
the PTPRC gene, were detected in rare cases of T-ALL.106
Remarkably, all CD45 mutations occurred in combination
with activating mutations in IL-7Ra, JAK1, or LCK.
Deletions or methylation of the PTPRK locus coding for a
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phosphatase that directly binds to and dephosphorylates
STAT3, were recently reported in 55% of nasal NK/T-cell
lymphomas.107
LNK is an adaptor protein that inhibits JAK2 activation
downstream of TPO-R and EPO-R.108 Mutations or dele-
tions in the pleckstrin-homology (PH) domain of LNK are
reported in rare cases of MPN.109,110 They occur either as an
isolated event in chronic phase diseases109 or concomitant-
ly with JAK2V617F mutation in patients who progress to
develop acute myeloid leukemia.110
SOCS1 mutations have been described in Hodgkin lym-
phomas and primary mediastinal B-cell lymphomas
(PMBCL).111 Reduced expression of SOCS1 and SOCS3,
related to hypermethylation of their promoter, has been
described in different lymphoid hematologic malignan-
cies,112 including MPN, in association113 or not114 with the
JAK2V617F mutation.
Taken together, these observations underline the role
played by deficiency of JAK-STAT negative regulation
processes in the pathogenesis of diverse hematologic neo-
plasms. Of note, such alterations can occur in concomi-
tance with activating receptor or JAK mutations meaning
that they are not mutually exclusive genetic events.104,106
Hence, it is postulated that loss of suppression does not
drive tumorigenesis directly, but rather contributes to
hyperactivation of the JAK-STAT pathway. Furthermore,
as tyrosine phosphatases are not JAK-restricted but have
multiple targets, their lack could exert broader oncogenic
effects on intracellular signaling, beyond the JAK-STAT
pathway. Finally, some of these alterations, such as PTPN2
deletions, reduce the sensitivity of transformed cells to
JAK inhibitors, so screening patients for such deletions
could be relevant for the prediction of treatment response. 
JAK inhibition in hematologic malignancies
The oncogene addiction concept postulates that, despite
the large number of genetic lesions conveyed by a single
cancer cell, some tumors rely on a single dominant onco-
gene for growth and survival, so that inhibition of this spe-
cific Achilles’ heel is sufficient to halt the neoplastic phe-
notype.115 At the clinical level, translation of the oncogene
addiction model into the rationale and effective design of
targeted therapeutics against individual oncoproteins is
best exemplified by the success story of imatinib, an ATP-
competitive tyrosine kinase inhibitor of BCR-ABL, which
dramatically prolonged the life expectancy of patients
with chronic myeloid leukemia.116 The finding of aberrant
JAK-STAT activation in a great majority of MPN and a sig-
nificant portion of other hematologic malignancies raised
the hope for an imatinib-like tyrosine kinase inhibitor
therapy. The heterogeneity in the nature of the underlying
genetic mechanisms could be overcome by exploiting the
signaling bottleneck provided by the limited number of
JAK kinases (Figure 4). However, it should be noted that
activating mutations in STAT factors are relatively insensi-
tive to JAK inhibitors.
Ruxolitinib in myeloid malignancies
The discovery of the MPN JAK2V617F mutation in 2005
has been rapidly exploited in the clinic. No more than 6
years later, ruxolitinib, a dual JAK1/2-specific ATP-com-
petitive inhibitor, was approved by the US Food and Drug
Administration for the treatment of intermediate- and
high-risk MF, a disease for which allogeneic stem cell
transplantation was the only curative option. In clinical tri-
als, ruxolitinib treatment was more effective at controlling
splenomegaly and alleviating MF-associated symptoms
than either placebo (COMFORT-I)117 or best available ther-
apy (COMFORT-II).118 Surprisingly, MF patients benefit
from ruxolitinib therapy regardless of their JAK2 muta-
tional status. Consistent with this unexpected observa-
tion, gene expression profiling data showed that MPN
samples are characterized by a shared transcriptional sig-
nature of activated JAK2-STAT5 signaling, irrespective of
disease phenotype or somatic genotype.119 Subsequent
identification of mutations in TPO-R and calreticulin,
which result in activation of the JAK2-STAT5 pathway as
discussed above, provided an explanation for this observa-
tion. The central role played by aberrant JAK-STAT path-
way activation in MPN gave a rationale for the unrestrict-
ed efficacy of ruxolitinib and raised the hope that patients
with mutation-positive and -negative PV, ET or MF
patients could efficiently respond to JAK inhibitors. 
However, ruxolitinib exerted only limited salutary
effects in terms of reversion of bone marrow fibrosis and
reduction of allele burden, suggesting that the concentra-
tion of the drug required to kill neoplastic cells is impossi-
ble to reach in patients without inducing serious adverse
events due to total inhibition of physiological cytokine
signaling. Indeed, because of its lack of specificity towards
JAK2-mutated forms, ruxolitinib impedes physiological
hematopoiesis leading to unwanted adverse events, the
most frequent being anemia and thrombocytopenia (inci-
dence >20%).120
Alternatively, the MPN cells might not be JAK2 onco-
gene-addicted and the benefit observed regarding consti-
tutional symptoms might be related to alleviation of the
pro-inflammatory tumor microenvironment rather than
selective suppression of the disease clone.117 The fact that
ruxolitinib also inhibits JAK1, an important player in
innate and specific immune responses, might contribute to
this anti-inflammatory activity. However, the drawback of
this JAK1 inhibition is reduced control of silent infections
and an increased incidence of opportunistic diseases, occa-
sionally observed upon long-term administration.121-124
Notwithstanding those side effects, the substantial
improvement in quality of life of MF patients encouraged
the conduction of additional clinical trials, with the pur-
pose of broadening the indications for ruxolitinib or test-
ing other JAK2 inhibitors. Recently, a phase III clinical
study aiming at evaluating the efficacy of ruxolitinib as
second-line treatment in PV patients intolerant to
hydroxy urea led to the conclusion that JAK2 inhibition
was superior to standard therapy in controlling hemat-
ocrit, reducing spleen size and improving PV-associated
symptoms.125 Ongoing phase III clinical trials in MF
patients are assessing the efficacy and safety of less myelo-
suppressive novel JAK2 inhibitors such as momelotinib
(CYT387) versus ruxolitinib (NCT01969838) and pacritinib
(SB1518) versus best available therapy (NCT01773187).
Besides classical MPN, a phase II trial is currently estimat-
ing the potential of ruxolitinib in chronic neutrophilic
leukemia and atypical chronic myeloid leukemia, in which
genetic activating alterations of CSF3R are encountered in
a significant proportion of cases, as described above, and
are associated with a poor outcome (NCT02092324).
Ruxolitinib has already proven effective in a CSF3RT618I
bone marrow transplant mouse model126 and one patient
with CSF3RT618I-positive atypical chronic myeloid
leukemia has been reported to have experienced a signifi-
L. Springuel et al.
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cant clinical response to ruxolitinib.127 Further encourage-
ment can be derived from reports of two patients with
PCM1-JAK2-positive chronic eosinophilic leukemia who
achieved complete hematologic and cytogenic responses
on ruxolitinib,128,129 although, in two other described cases,
rapid remission was only of limited duration and relapse
occurred within 24 months.130
Ruxolitinib in lymphoid malignancies
In pre-clinical experiments, ruxolitinib treatment yield-
ed a significant decrease of circulating blast counts in
murine xenograft models of Philadelphia chromosome
(Ph)-like B-ALL131 and early T-cell precursor (ETP)-ALL,132
two recently described high-risk subtypes of ALL with
aberrant activation of the JAK-STAT pathway for which
novel therapies are needed. In the ETP-ALL model, the
efficacy of treatment was independent of the presence of
JAK-STAT mutations, raising the possibility that the ther-
apeutic potential of ruxolitinib extends beyond the cases
with JAK-STAT mutations.132 As suggested for MPN, a JAK
activation footprint may be more significant than the pres-
ence of a mutation for predicting response to therapy. This
notion greatly increases the numbers of patients that could
potentially benefit from JAK inhibitors and will probably
motivate the setting up of future clinical trials in lymphoid
malignancies. A recent clinical report described a unique
case of a patient with refractory PMBCL with an activat-
ing JAK3 mutation (A573V) who experienced partial dis-
ease remission upon treatment with tofacitinib, a JAK1/3-
specific inhibitor, in combination with immuno-
chemotherapy.133
JAK inhibitor resistance in hematologic malignancies
Although ruxolitinib has proven effective in patients
with MF, some of them experienced treatment failure.134
Besides discontinuation due to drug-related toxicity (such
as early-onset cytopenias), ruxolitinib treatment failure in
MF manifests as primary refractoriness or secondary
resistance. Primary refractoriness can be defined as no or
only minimal clinical response (<35% reduction of spleen
volume compared to baseline), whereas secondary resist-
ance is indicated by the loss of a previously confirmed
clinical response (such as splenic relapse) or progression to
leukemia.120 In a cohort of 39 ruxolitinib-treated MF
patients, resistance was observed in 41% of cases, mostly
as a late event (after a median exposure of 1 year) and
rarely as primary refractoriness (<10%). The same study
identified a significant correlation between resistance and
the absence of mutations in JAK2 (V617F), MPL, TET2,
and SRSF2 at diagnosis.135
Based on clinical experiences with other tyrosine kinase
inhibitor therapies, it could be expected that resistant
patients would have acquired mutations at the drug-bind-
ing site of the target kinase, as illustrated by the emer-
gence of BCR-ABL mutations in patients with chronic
myeloid leukemia.116 A dozen different point mutations
conferring resistance to ruxolitinib were discovered using
in vitro random mutagenesis screens of JAK2 and in vitro
selection of spontaneous resistant cell lines.78,136-138
However, no mutations in JAK2 could be detected in
patients treated with ruxolitinib, indicating that this
mechanism is rarely involved in clinical resistance.135
Tolerable doses of ruxolitinib provide only partial inhibi-
tion of the kinase, so the therapeutic pressure may be
insufficient for the selection of resistant mutants. Rather,
chronic exposure to suboptimal inhibitor concentrations
might favor less drastic escape mechanisms. A reversible
stage of so-called “inhibitor persistence” has been
observed in ruxolitinib-treated patients and in JAK2V617F-
transformed cell lines cultured with gradually increasing
doses of ruxolitinib in vitro.139 Cells were allowed to persist
despite JAK2 inhibition thanks to restoration of JAK–STAT
signaling via overexpression of JAK2, which facilitates its
heterodimeric transactivation with JAK1 or TYK2.
Interestingly, inhibitors of HSP90, a chaperone known to
stabilize JAK2, synergize with JAK2 inhibitors and over-
come TKI persistence as well as genetic resistance.137,139,140 A
phase II study is currently evaluating the potency of a
HSP90 inhibitor in MF and refractory PV/ET patients
(NCT01668173).
Perspectives for the use of JAK inhibitors 
in hematologic malignancies
At present, clinical data revealed that the targeted ther-
apy concept prompted by the success story of imatinib
would be more complex to apply with JAK inhibitors. The
incapacity of ruxolitinib to reduce allele burden is poten-
tially due to the absence of strong JAK2 oncogene addic-
tion of MPN cells as discussed before. Nevertheless,
broader investigations are encouraged by the substantial
benefit of JAK2 inhibition irrespective of mutational status
in MPN patients, preclinical evidence for ruxolitinib indi-
cations in other malignancies (chronic neutrophilic
leukemia, ETP-ALL, Ph-like ALL) and significant clinical
responses to JAK inhibitors in rare case reports (CSF3RT618I-
positive or PCM1-JAK2-positive MPN and a JAK3A573V-pos-
itive PMBCL). 
A second hurdle is the lack of selectivity of the currently
used inhibitors, which implies that the tolerable doses lie
within a narrow therapeutic window because of the col-
lateral inhibition of other JAK members. Specific
inhibitors for one of the four closely related JAK kinases
could partially tackle this drawback but is difficult to
achieve because of the marked similarity in the active site
within the family. Ruxolitinib (and other JAK inhibitors
under clinical evaluation) falls within the so-called type I
family, which means that it precisely targets the well-con-
served ATP-binding pocket of JAK1 and JAK2 in both
active and inactive conformations.141,142 By contrast,
inhibitors that have a type II binding-mode (such as ima-
tinib) specifically engage and stabilize inactive kinases by
exploiting an additional, less conserved allosteric site
directly adjacent to the ATP binding pocket, providing
another handle for tuning selectivity.141 Type II inhibition
of JAK2 with NVP-CHZ868 demonstrated potent disease-
modifying activity with significant reduction of allele bur-
den in different in vivo MPN models.143 Alternatively, a
covalent inhibitor exploiting a non-conserved cystein
residue in the active site of JAK3 has been shown to have
strong target specificity.144 Very recently, a new class of
inhibitors was found to bind to and lock the pseudokinase
domain of TYK2 in a conformation that stabilizes the
autoinhibitory interaction with the adjacent kinase
domain, preventing its receptor-mediated activation.145
These JH2 stabilizers occupy a site analogous to the ATP-
binding site in catalytic kinases by forming hydrogen
bonds with non-conserved residues, providing a novel
approach for the design of highly selective inhibitors.145
Paradoxically, increasing specificity by development of
type II, covalent or JH2 inhibitors could result in a decrease
JAK kinase targeting in hematologic malignancies
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JAK2 at the apex of downstream signal propagation medi-
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PI3K/Akt/mTOR, MAPK) that synergistically act on cell
proliferation.146 Activation of the PI3K/Akt/mTOR path-
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as well as JAK2V617F-induced tumorigenesis in mice147 and
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pendent groups demonstrated that combining ruxolitinib
with a PI3K inhibitor synergistically inhibited proliferation
of in vitro MPN cell models and reduced spleen weight in
preclinical MPN models.149,150 A similar synergistic action
was also observed between mTOR and JAK2 inhibitors.151
A translational phase I clinical study is currently evaluating
the safety and maximal tolerated doses of the combination
of ruxolitinib and BKM120, a PI3K inhibitor, in MF patients
(NCT01730248). In addition to further clinical benefit,
simultaneous blockade of oncogenic signaling at multiple
levels by combined therapy approaches (such as ruxolinitib
with PI3K inhibitors or HSP90 inhibitors) might avoid the
emergence of resistance by distributing the selective pres-
sure between distinct targets. 
Conclusion
A promising future is awaiting JAK inhibitors in the
therapeutic arsenal of hematologic malignancies provid-
ed that appropriate indications are identified.
Contrasting with the direct connection between ima-
tinib and BCR-ABL-positive leukemias, the path to
determining relevant applications for JAK inhibitors is
more sinuous. First, the genetic alterations converging
towards constitutive JAK activation are diverse and
sometimes unexpected, such as the recently discovered
calreticulin mutations. Furthermore, certain subtypes of
ALL display an activated JAK transcriptional signature in
the absence of known genetic abnormalities and
respond to JAK inhibitor treatment in preclinical models,
which makes the identification of suitable clinical indi-
cations even more complex. Second, once targetable
candidate diseases have been selected, their JAK onco-
gene-addiction will remain to be validated clinically.
Finally, the optimal therapeutic window is narrowed by
the collateral inhibition of non-mutated JAK, with a fine
balance between, on the one hand, adverse side effects
due to impairments of physiological processes such as
hematopoiesis or immunity and, on the other hand, ben-
eficial contributions of alleviating the cancer-related pro-
inflammatory microenvironment. It is, therefore, very
likely that JAK inhibitors combined with other targeted
therapies will be more efficient in synergistically modi-
fying the natural history of the disease, overcoming
inhibitor persistence and preventing the emergence of
resistant subclones. 
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